PCSK9 inhibition as a routine early therapy for ST segment elevation myocardial infarction (STEMI) patients – in addition to statins – should be investigated in a large outcomes trial after a 68-patient randomized trial showed a 22% low-density lipoprotein (LDL) cholesterol reduction versus sham control, an investigator urged on Monday.